Physician profile
Anuj Chandra
NPI 1710977301
$19,871.82
in general payments reported to CMS, 2019-2025
23 companies · $775 in 2025
The $775 reported for 2025 was more than what a typical Sleep Medicine (Internal Medicine) provider received nationally (typical 2025 total: $447).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,109 · 2020: $348 · 2021: $616 · 2022: $3,920 · 2023: $12K · 2024: $1,226 · 2025: $775.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,442 · Food and Beverage: $2,877 · Travel and Lodging: $1,445 · Consulting Fee: $1,048 · Education: $67.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,442.00 |
| Food and Beverage | $2,877.33 |
| Travel and Lodging | $1,445.24 |
| Consulting Fee | $1,047.50 |
| Education | $67.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $11,714.52 | 2020-2025 | Wakix |
| Inspire Medical Systems, INC. | $3,505.50 | 2019-2025 | Inspire |
| Jazz Pharmaceuticals INC. | $1,470.44 | 2019-2025 | Xywav |
| Axsome Therapeutics, INC. | $600.41 | 2023-2025 | Sunosi |
| Biohaven Pharmaceutical Holding Company Ltd. | $503.91 | 2022 | |
| Philips North America LLC | $439.75 | 2019-2024 | (7999) Src Und |
| 3b Medical, INC. | $298.33 | 2023-2025 | Luna |
| Merck Sharp & Dohme LLC | $214.26 | 2019-2023 | Belsomra |
| Glaxosmithkline, LLC. | $205.02 | 2019-2020 | |
| Resmed Corp | $154.00 | 2020-2024 | |
| United Therapeutics Corporation | $147.82 | 2024 | Tyvaso |
| Fisher & Paykel Healthcare INC | $141.65 | 2019-2024 | Fisher & Paykel Healthcare |
| Zoll Respicardia, INC. | $87.10 | 2024 | Remede System |
| Eisai INC. | $67.65 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $67.27 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aytu Biopharma, INC. | $55.96 | 2019-2021 | |
| Insmed, INC. | $44.62 | 2024-2025 | Brinsupri, Arikayce |
| Lilly USA, LLC | $39.34 | 2025 | Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.46 | 2024 | Ofev |
| Idorsia Pharmaceuticals US INC | $29.54 | 2023-2024 | Quviviq |
| Azurity Pharmaceuticals, INC. | $21.75 | 2024 | Horizant |
| Ucb, INC. | $19.12 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $13.40 | 2024 | Breztri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anuj Chandra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.